Sanofi Says Phase 3 Study of Sarclisa Showed Longer Progression-Free Survival
2022年5月16日 - 2:53PM
Dow Jones News
By Cristina Roca
Sanofi SA on Sunday reported positive results from a Phase 3
trial of its Sarclisa treatment in combination with other therapies
in patients with relapsed multiple myeloma.
The French pharmaceutical company said patients showed
significantly longer median progression-free survival when using
Sarclisa on top of carfilzomib and dexamethasone.
Multiple myeloma is a hematologic malignancy that doesn't have a
cure, Sanofi said. Relapsed multiple myeloma is the term for when
the cancer returns after treatment or a period of remission.
Write to Cristina Roca at cristina.roca@wsj.com
(END) Dow Jones Newswires
May 16, 2022 01:38 ET (05:38 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
過去 株価チャート
から 3 2024 まで 4 2024
Sanofi (EU:SAN)
過去 株価チャート
から 4 2023 まで 4 2024
